GlassScriptPhysician profile
Rebecca Goldstein
NPI 1205327624
$222.00
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.57 · 2022: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $75.45 | 2021-2022 | |
| Kaleo, INC. | $41.55 | 2021-2022 | |
| Glaxosmithkline, LLC. | $23.65 | 2022 | |
| Merck Sharp & Dohme LLC | $23.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.22 | 2021 | |
| Neos Therapeutics, LP | $21.84 | 2022 | |
| Oxford Immunotec USA INC | $14.26 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.